Tehran University of Medical Sciences Iranian Journal of Psychiatry 1735-4587 12 2 2017 04 23 142 146 EN Azadeh Moghaddas Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran. Mehrnoush Dianatkhah Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Saba Ghaffari Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Padideh Ghaeli Psychiatry and Psychology Research Center, Roozbeh Hospital and Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 2017 04 22 Objective: Management of borderline personality disorder (BPD) is a difficult challenge due to the complex features of this disorder. This article reviews the use of naltrexone in the treatment of BPD. Methods: Published articles and clinical trials were searched in Google Scholar, MedLine, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017. Results: Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling selfinjurious behavior (SIB) and dissociative symptoms in patients with BPD. Conclusions: Further studies should be conducted on the effects of naltrexone to confirm the role of this medication in the treatment of BPD. https://ijps.tums.ac.ir/index.php/ijps/article/view/1041 https://ijps.tums.ac.ir/index.php/ijps/article/download/1041/618